ReviewBioresources and bioprocessing2026
Artificial intelligence and automation in enzyme engineering: evolution, advances, and future perspectives.
Review in Bioresources and bioprocessing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Natural enzymes often fail to meet industrial demands for catalytic efficiency, stability, and substrate specificity, creating a critical bottleneck in biomanufacturing. This review examines how artificial intelligence (AI) and automation are reshaping enzyme engineering from empirical trial‑and‑error toward data-driven, closed-loop design. We trace AI development from feature-engineered machine learning to supervised deep learning and self-supervised protein language models, and automation from standalone task execution to cascade integration and biofoundry-enabled build-test workflows. Their convergence is analyzed through a stage-based autonomy framework, highlighting the transition from semi-automated workflows to conditional and high-autonomy DBTL systems. Recent studies demonstrate that AI-guided prediction, automated experimentation, and active learning can accelerate enzyme optimization; however, key barriers remain, including biased datasets, limited out-of-distribution generalization, weak mechanistic interpretability, automation interoperability constraints, and unresolved multi-objective trade-offs. We discuss future directions involving FAIR-compliant data infrastructure, hybrid sequence-structure-physics models, modular automation platforms, and autonomous closed-loop systems. By integrating historical evolution, representative case studies, success and failure analysis, and practical bottlenecks, this review provides a roadmap for advancing AI-guided and autonomous enzyme engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.